Alniche Lifesciences on LinkedIn: #isnnorthzone2024 #alniche #pharma #conference2024 (2024)

Day 1 of the MarketsandMarkets Biomarker and Companion Diagnostics Conference - EU Edition was an absolute success! The Westin Grand Frankfurt, Germany, played host to some of the brightest minds in the industry, including Allan Stensballe (ATV) | Elizabeth A. Sheppard | Eike Staub | Shidong Jia | Liying Yan | Louis Boon | Philip Beer | Illip Burmester | Christopher Peters | Vaios Karanikas | Aparna D. who shared their invaluable insights. We're energized and ready for an even more enlightening Day 2. Stay tuned!#biomarker#personalizedmedicine#biomarkervalidation#companiondiagnostics#healthcare#pharma#healthcaretechnology#marketsandmarkets#ConferenceRegistration#BiomarkerConference#CompanionDiagnostics

16

Propulsion of Hypovolemia Clinical Trial Pipeline as Novel and Extensive 10+ Therapies Likely to Enter in the Domain | DelveInsight: (Albany, United States) As per DelveInsight’s assessment, globally, the Hypovolemia Pipeline constitutes 10+ key companies continuously working towards developing 10+ Hypovolemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. … Continue reading → #HealthMedicine #PharmaceuticalsBiotech #Services

At the recent German Network for Personalised Medicine (DNPM) congress, Josef Hecken, chairman of the Federal Joint Committee (G-BA),shared key shared innovative approaches to evidence generation and patient care, signalling a shift from traditional drug trials.This could mean easier access to personalised therapies, benefiting both patients and manufacturers.🏥 Dive into the details and implications of this transformative change in our latest insider insight ➡ 🔗 https://lnkd.in/evj6naTn#MarketAccess #PatientAccess #PersonalisedMedicine #HealthcareInnovation #DrugTrials #Pharma #Biotech #PatientCare* 𝒘𝒓𝒊𝒕𝒕𝒆𝒏 𝒃𝒚 Manahill Baig

3

Chronic hemodialysis is a medical procedure used to treat individuals with end-stage renal disease (ESRD) or severe kidney failure. It involves using a machine to filter waste products and excess fluid from the blood when the kidneys are no longer able to perform this function adequately.The leading Chronic Hemodialysis Companies working in the market include Cara Therapeutics Inc., Bayer, Novartis Pharma, , Pfizer, Medtronic, Abbott, Baxter International Inc., Rockwell Medical, Inc., Astellas Pharma Inc., Merit Medical Systems, Inc., and others.According to DelveInsight Business Research LLP, the Chronic Hemodialysis market in 7MM is expected to witness a major change in the upcoming years.To get more detailed information on chronic hemodialysis, visit: https://lnkd.in/dN7Nq7yk

6

Chronic illnesses have become more and more prevalent in recent years. With them, drug complexity and delivery methods are getting increasingly intricate.#Pharma companies face an exciting mission: to create groundbreaking therapies with unique formulation needs.Peter Droc, Head of Drug Product Services at Lonza, brilliantly summarizes some of our solutions to complex formulation requirements: https://lnkd.in/dKCPqaHu Isn't it fascinating how we can ensure quality and patient safety, while also decreasing time-to-market?#Lonza #DrugProduct

13

The significance of #biosimilars extends beyond cost reduction. In the early development stages, they open avenues for innovative drug development approaches, enhancing cost-effective #treatment options and accessibility. Thanks to biosimilars,more #patients worldwide can benefit from the latest advancements in drug development. We pave the way for healthcare systems that prioritize patient well-being and #sustainability ♻️🌍

8

Losing sleep over NDSRIs and genotoxic impurities? Worry no more!Join us at the 2nd Annual Pharma Impurities Conclave 2024 in Hyderabad on September 12th -13th, 2024 where leading experts will share their secrets and cutting-edge strategies to tackle these challenges.REGISTER NOW: https://lnkd.in/gMdQsYvw#eminencebusinessmedia #ebmpic2024 #eminencegroupventures

27

Empros Pharma's latest weight loss drug might not be able to compete with the big players in the market, but that's not their aim. The Swedish biotech is targeting people who want to maintain their weight loss after taking a GLP-1, and those who are overweight or on the lower end of the obesity scale.The topline data just released shows that the drug, EMP16, delivered an average weight loss of nearly 8%, with a third of patients losing at least 10% of their body weight. With responders losing up to 23% over the six-month, 320-patient study, Empros CEO Arvid Söderhäll expects an average 10% weight loss over a full year.While the drug might not be a match for big players like Wegovy and Zepbound, it shows promise for those looking to maintain their weight loss.

4

MPO – Spot Check: A Discussion of the In-Vitro Diagnostics MarketCurious about the latest trends and challenges in IVD? Dive into our insightful discussion here:https://lnkd.in/eFixdnzQJohn Faulkner, Vice President of Sales and Marketing is one of nine industry experts who provide trends and challenges shaping the future of the In-vitro Diagnostics market.Home testing and self-collection represent just a fraction of the vast IVD testing market. To paint a comprehensive picture of its dynamics, MPO has engaged with leading voices in the field.#InVitroDiagnostics #IVD #HealthcareTrends #MedicalDevices #HealthTech #Biotechnology #HealthcareInnovation #MedicalIndustry #HealthcareProfessionals #MedTech #IndustryInsights #SpotCheck #HealthcareDiscussion

3

As of August 2023, there were 40 FDA-approved biosimilar products, including 25 commercially available products and four with interchangeable status. In this infographic, #CRALifeSciences Brendan Kelly, Ph.D., Travis Ruch, Ph.D., and Emma C. focus on three Infliximab biosimilars that have launched in the US. A key question remains: do biologic-naïve (“new”) or biologic-experienced (“switch”) patients drive biosimilar uptake? Read the infographic to learn more: https://crai.news/3dd.

19